Analyst Price Targets — ADMA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 20, 2026 8:20 pm | — | Canaccord Genuity | $21.00 | $10.88 | TheFly | Adma Biologics initiated with a Buy at Canaccord |
| April 13, 2026 2:35 pm | Anthony Petrone | Mizuho Securities | $24.00 | $10.33 | TheFly | Adma Biologics price target lowered to $24 from $30 at Mizuho |
| October 14, 2024 6:58 am | Raghuram Selvaraju | H.C. Wainwright | $18.00 | $17.15 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on ADMA Biologics (ADMA) |
| June 20, 2024 6:47 am | Anthony Petrone | Mizuho Securities | $14.00 | $10.62 | StreetInsider | ADMA Biologics (ADMA) PT Raised to $14 at Mizuho |
| January 3, 2023 6:14 am | — | H.C. Wainwright | $4.50 | $3.88 | Benzinga | HC Wainwright & Co. Maintains Buy on ADMA Biologics, Raises Price Target to $4.5 |
| November 10, 2022 10:24 am | — | Mizuho Securities | $6.00 | $3.05 | Benzinga | Mizuho Maintains Buy on ADMA Biologics, Raises Price Target to $6 |
| July 25, 2022 6:44 am | — | H.C. Wainwright | $4.00 | $2.17 | Benzinga | HC Wainwright & Co. Maintains Buy on ADMA Biologics, Lowers Price Target to $4 |
Latest News for ADMA
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, continues its investigation on behalf of ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ: ADMA) investors concerning the Company's possible violations of the federal securities laws.
NEW YORK, April 20, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of ADMA Biologics, Inc. (NASDAQ: ADMA) resulting from allegations that ADMA Biologics may have issued materially misleading business information to the investing public. So What: If you purchased ADMA Biologics securities you may be…
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith continues its investigation on behalf of ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ: ADMA) investors concerning the Company's possible violations of federal securities laws.
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz continues its investigation of ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ: ADMA) on behalf of investors concerning the Company's possible violations of federal securities laws.
NEW YORK, April 20, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ:ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/adma-biologics-class-action-lawsuit.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ADMA.
U.S. House Trading
No House trades found for ADMA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.